Unified Patent Court (UPC) analytics are now available. Check here

PatentPatent Analysis

EP2991671

NOVO NORDISK
Application Number
EP14721834A
Filing Date
May 2, 2014
Status
Revoked
Mar 22, 2024
Grant Date
Aug 15, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2991671B1 was granted on Aug 15, 2018 by Novo Nordisk The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUMay 15, 2019ADMISSIBLE
GENERICS UKMay 15, 2019ADMISSIBLE
HEXALMay 15, 2019ADMISSIBLE
KRAUS & LEDERER PARTGMBBMay 15, 2019ADMISSIBLE
SANOFIMay 15, 2019ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESMay 13, 2019ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionEP2651398B1
N/A
OppositionEP2991671B1
N/A
OppositionWO2006097537
N/A
OppositionWO2012080471
N/A
OppositionWO2008033888
N/A
OppositionUS2013053311
N/A
OppositionEP2565202
N/A
OppositionWO2013139695
N/A
OppositionWO2013139694
N/A
OppositionWO2012140117
N/A
OppositionWO2013009545
N/A
OppositionWO2014177683
N/A
OppositionWO2007061434
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.